Skip to main content

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting · Phase 3 · NCT05869903

Conditions: Obesity, Overweight, Overweight or Obesity

At a glance

Research payments reported, 2025
$7.6M
U.S. investigators named
61
Sites paid
54
Planned or actual enrollment
3,127

About the trial

Sponsor
Eli Lilly and Company
Tested
Orforglipron (drug), Placebo (drug)
Dates
Started 2023-06-05; completion 2027-10
Results posted
Yes

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

From ClinicalTrials.gov, last updated 2026-08-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $7.6M in research payments for this study in 2025 (119 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Sky Clinical Research Network Group $475,370
  • New Age Medical Research Corp $401,329
  • Dorado Medical Complex Inc $327,847
  • Cedar Health Research $318,889
  • Arcturus Healthcare PLC, Troy Internal $313,225
  • Cotton Oneil Msd of Stormont Vail Healthcare $310,622
  • Velocity Clinical Research Inc $309,156
  • Yshay Shlesinger MD $259,696
  • South Broward Research, LLC $256,332
  • Soma Clinical Trials LLC $251,830
  • David Fitzpatrick MD DBA E West Med Rsrch $240,879
  • Eastside Research Associates LLC $225,621
  • Medstar Health Research Institute $222,808
  • Gcm Medical Group Psc $203,331
  • Long Island Cardiovascular Imaging Consultants PC $192,230
  • Elite Clinical Trials Lllp $185,543
  • Norcal Medical Research Inc $183,817
  • Consano Clinical Research LLC $172,037
  • Health Research of Hampton Roads $170,303
  • Regents of the University of Colorado $167,941
  • Weill Medical College $165,846
  • John Muir Med Fndtn DBA John Muir Phys Network $165,181
  • Renstar Inc $162,282
  • Clinical Research Institute of Arizona LLC $153,929
  • Jedidiah Clinical Research $150,804
  • Headlands Research California LLC $147,395
  • Juno Research LLC $146,072
  • East Coast Institute for Research $144,803
  • Alliance for Multispecialty Research Lls $144,596
  • Board of Supervisors of La State $143,559
  • Texas Diabetes and Endocrinology PA $137,013
  • Clinical Site PArtners LLC $118,239
  • Catalina Research Institute LLC $109,472
  • University Clinical Investigators Inc $104,977
  • Las Vegas Medical Research LLC $104,733
  • Thyroid, Endocrinology, and Diabetes, PA, $84,876
  • Care Access Research LLC $79,805
  • Institute for Liver Health LLC $77,453
  • Helena W Rodbard, MD, PA $61,096
  • Physicians Research $14,724
  • Cleveland Clinic, OH $3,023
  • Andrew J Lewin Med DBA National Rsrch Institute $1,444
  • Weill Cornell Medical College $1,171
  • Amcr Institute Inc $1,165
  • University of Colorado Hospital Authority, CO $799
  • Monroe Biomedical Research $720
  • New England Research Associates LLC $662
  • Clinical Research Institute Inc $539
  • Elite Clinical Trials Inc DBA Elliot Moon $490
  • Seattle Institute for Biomed and Clinical Rsrch $484
  • Vancouver Clinic Inc Ps $308
  • Hattiesburg Clinic PA $195
  • $174
  • Dallas Diabetes and Endo Research Center PA $105
  • Studymetrix Research LLC $65

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.